Lack of aprataxin impairs mitochondrial functions via downregulation of the APE1/NRF1/NRF2 pathway

Beatriz Garcia-Diaz, Emanuele Barca, Andrea Balreira, Luis C. Lopez, Saba Tadesse, Sindhu Krishna, Ali Naini, Caterina Mariotti, Barbara Castellotti, Catarina M. Quinzii

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Ataxia oculomotor apraxia type 1 (AOA1) is an autosomal recessive disease caused by mutations in APTX, which encodes the DNA strand-break repair protein aprataxin (APTX). CoQ10 deficiency has been identified in fibroblasts and muscle of AOA1 patients carrying the common W279X mutation, and aprataxin has been localized to mitochondria in neuroblastoma cells, where it enhances preservation of mitochondrial function. In this study, we show that aprataxin deficiency impairs mitochondrial function, independent of its role in mitochondrial DNA repair. The bioenergetics defect in AOA1-mutant fibroblasts and APTX-depleted Hela cells is caused by decreased expression of SDHA and genes encoding CoQ biosynthetic enzymes, in association with reductions of APE1, NRF1 and NRF2. The biochemical and molecular abnormalities in APTX-depleted cells are recapitulated by knockdown of APE1 in Hela cells and are rescued by overexpression of NRF1/2. Importantly, pharmacological upregulation of NRF1 alone by 5-aminoimidazone-4-carboxamide ribonucleotide does not rescue the phenotype, which, in contrast, is reversed by the upregulation of NRF2 by rosiglitazone. Accordingly, we propose that the lack of aprataxin causes reduction of the pathway APE1/NRF1/NRF2 and their target genes. Our findings demonstrate a critical role of APTX in transcription regulation of mitochondrial function and the pathogenesis of AOA1 via a novel pathomechanistic pathway, which may be relevant to other neurodegenerative diseases.

Original languageEnglish
Article numberddv183
Pages (from-to)4516-4529
Number of pages14
JournalHuman Molecular Genetics
Volume24
Issue number16
DOIs
Publication statusPublished - Apr 28 2015

Fingerprint

Down-Regulation
coenzyme Q10
rosiglitazone
HeLa Cells
Up-Regulation
Fibroblasts
Ribonucleotides
Mutation
DNA Breaks
Neuroblastoma
Mitochondrial DNA
DNA Repair
Neurodegenerative Diseases
Energy Metabolism
Mitochondria
Pharmacology
Phenotype
Gene Expression
Muscles
Early-onset ataxia with oculomotor apraxia and hypoalbuminemia

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology

Cite this

Garcia-Diaz, B., Barca, E., Balreira, A., Lopez, L. C., Tadesse, S., Krishna, S., ... Quinzii, C. M. (2015). Lack of aprataxin impairs mitochondrial functions via downregulation of the APE1/NRF1/NRF2 pathway. Human Molecular Genetics, 24(16), 4516-4529. [ddv183]. https://doi.org/10.1093/hmg/ddv183

Lack of aprataxin impairs mitochondrial functions via downregulation of the APE1/NRF1/NRF2 pathway. / Garcia-Diaz, Beatriz; Barca, Emanuele; Balreira, Andrea; Lopez, Luis C.; Tadesse, Saba; Krishna, Sindhu; Naini, Ali; Mariotti, Caterina; Castellotti, Barbara; Quinzii, Catarina M.

In: Human Molecular Genetics, Vol. 24, No. 16, ddv183, 28.04.2015, p. 4516-4529.

Research output: Contribution to journalArticle

Garcia-Diaz, B, Barca, E, Balreira, A, Lopez, LC, Tadesse, S, Krishna, S, Naini, A, Mariotti, C, Castellotti, B & Quinzii, CM 2015, 'Lack of aprataxin impairs mitochondrial functions via downregulation of the APE1/NRF1/NRF2 pathway', Human Molecular Genetics, vol. 24, no. 16, ddv183, pp. 4516-4529. https://doi.org/10.1093/hmg/ddv183
Garcia-Diaz B, Barca E, Balreira A, Lopez LC, Tadesse S, Krishna S et al. Lack of aprataxin impairs mitochondrial functions via downregulation of the APE1/NRF1/NRF2 pathway. Human Molecular Genetics. 2015 Apr 28;24(16):4516-4529. ddv183. https://doi.org/10.1093/hmg/ddv183
Garcia-Diaz, Beatriz ; Barca, Emanuele ; Balreira, Andrea ; Lopez, Luis C. ; Tadesse, Saba ; Krishna, Sindhu ; Naini, Ali ; Mariotti, Caterina ; Castellotti, Barbara ; Quinzii, Catarina M. / Lack of aprataxin impairs mitochondrial functions via downregulation of the APE1/NRF1/NRF2 pathway. In: Human Molecular Genetics. 2015 ; Vol. 24, No. 16. pp. 4516-4529.
@article{7d30b9132d994a51ae70d74383a26e5a,
title = "Lack of aprataxin impairs mitochondrial functions via downregulation of the APE1/NRF1/NRF2 pathway",
abstract = "Ataxia oculomotor apraxia type 1 (AOA1) is an autosomal recessive disease caused by mutations in APTX, which encodes the DNA strand-break repair protein aprataxin (APTX). CoQ10 deficiency has been identified in fibroblasts and muscle of AOA1 patients carrying the common W279X mutation, and aprataxin has been localized to mitochondria in neuroblastoma cells, where it enhances preservation of mitochondrial function. In this study, we show that aprataxin deficiency impairs mitochondrial function, independent of its role in mitochondrial DNA repair. The bioenergetics defect in AOA1-mutant fibroblasts and APTX-depleted Hela cells is caused by decreased expression of SDHA and genes encoding CoQ biosynthetic enzymes, in association with reductions of APE1, NRF1 and NRF2. The biochemical and molecular abnormalities in APTX-depleted cells are recapitulated by knockdown of APE1 in Hela cells and are rescued by overexpression of NRF1/2. Importantly, pharmacological upregulation of NRF1 alone by 5-aminoimidazone-4-carboxamide ribonucleotide does not rescue the phenotype, which, in contrast, is reversed by the upregulation of NRF2 by rosiglitazone. Accordingly, we propose that the lack of aprataxin causes reduction of the pathway APE1/NRF1/NRF2 and their target genes. Our findings demonstrate a critical role of APTX in transcription regulation of mitochondrial function and the pathogenesis of AOA1 via a novel pathomechanistic pathway, which may be relevant to other neurodegenerative diseases.",
author = "Beatriz Garcia-Diaz and Emanuele Barca and Andrea Balreira and Lopez, {Luis C.} and Saba Tadesse and Sindhu Krishna and Ali Naini and Caterina Mariotti and Barbara Castellotti and Quinzii, {Catarina M.}",
year = "2015",
month = "4",
day = "28",
doi = "10.1093/hmg/ddv183",
language = "English",
volume = "24",
pages = "4516--4529",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "16",

}

TY - JOUR

T1 - Lack of aprataxin impairs mitochondrial functions via downregulation of the APE1/NRF1/NRF2 pathway

AU - Garcia-Diaz, Beatriz

AU - Barca, Emanuele

AU - Balreira, Andrea

AU - Lopez, Luis C.

AU - Tadesse, Saba

AU - Krishna, Sindhu

AU - Naini, Ali

AU - Mariotti, Caterina

AU - Castellotti, Barbara

AU - Quinzii, Catarina M.

PY - 2015/4/28

Y1 - 2015/4/28

N2 - Ataxia oculomotor apraxia type 1 (AOA1) is an autosomal recessive disease caused by mutations in APTX, which encodes the DNA strand-break repair protein aprataxin (APTX). CoQ10 deficiency has been identified in fibroblasts and muscle of AOA1 patients carrying the common W279X mutation, and aprataxin has been localized to mitochondria in neuroblastoma cells, where it enhances preservation of mitochondrial function. In this study, we show that aprataxin deficiency impairs mitochondrial function, independent of its role in mitochondrial DNA repair. The bioenergetics defect in AOA1-mutant fibroblasts and APTX-depleted Hela cells is caused by decreased expression of SDHA and genes encoding CoQ biosynthetic enzymes, in association with reductions of APE1, NRF1 and NRF2. The biochemical and molecular abnormalities in APTX-depleted cells are recapitulated by knockdown of APE1 in Hela cells and are rescued by overexpression of NRF1/2. Importantly, pharmacological upregulation of NRF1 alone by 5-aminoimidazone-4-carboxamide ribonucleotide does not rescue the phenotype, which, in contrast, is reversed by the upregulation of NRF2 by rosiglitazone. Accordingly, we propose that the lack of aprataxin causes reduction of the pathway APE1/NRF1/NRF2 and their target genes. Our findings demonstrate a critical role of APTX in transcription regulation of mitochondrial function and the pathogenesis of AOA1 via a novel pathomechanistic pathway, which may be relevant to other neurodegenerative diseases.

AB - Ataxia oculomotor apraxia type 1 (AOA1) is an autosomal recessive disease caused by mutations in APTX, which encodes the DNA strand-break repair protein aprataxin (APTX). CoQ10 deficiency has been identified in fibroblasts and muscle of AOA1 patients carrying the common W279X mutation, and aprataxin has been localized to mitochondria in neuroblastoma cells, where it enhances preservation of mitochondrial function. In this study, we show that aprataxin deficiency impairs mitochondrial function, independent of its role in mitochondrial DNA repair. The bioenergetics defect in AOA1-mutant fibroblasts and APTX-depleted Hela cells is caused by decreased expression of SDHA and genes encoding CoQ biosynthetic enzymes, in association with reductions of APE1, NRF1 and NRF2. The biochemical and molecular abnormalities in APTX-depleted cells are recapitulated by knockdown of APE1 in Hela cells and are rescued by overexpression of NRF1/2. Importantly, pharmacological upregulation of NRF1 alone by 5-aminoimidazone-4-carboxamide ribonucleotide does not rescue the phenotype, which, in contrast, is reversed by the upregulation of NRF2 by rosiglitazone. Accordingly, we propose that the lack of aprataxin causes reduction of the pathway APE1/NRF1/NRF2 and their target genes. Our findings demonstrate a critical role of APTX in transcription regulation of mitochondrial function and the pathogenesis of AOA1 via a novel pathomechanistic pathway, which may be relevant to other neurodegenerative diseases.

UR - http://www.scopus.com/inward/record.url?scp=84939490615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939490615&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddv183

DO - 10.1093/hmg/ddv183

M3 - Article

VL - 24

SP - 4516

EP - 4529

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 16

M1 - ddv183

ER -